Skip to content

Lipoprotein (a) and Vascular Regenerative Cell Content

Dyslipidemia | Cardiovascular Diseases | Ischemic Heart Disease | Atherosclerosis Cardiovascular Disease

Lp(a)-VRCE is an observational, cross sectional study looking at vessel reparative stem cell content in people with and without elevated lipoprotein (a) \[Lp(a)\]. Specifically, the type and number of these cells in peripheral blood samples will be measured in participants with Lp(a) ≥100 nmol/L and compared to participants with Lp(a) \< 100 nmol/L. Determining the presence or absence of specific cells with blood vessel repair capacity in participants with high Lp(a) will further our knowledge of potential mechanisms through which Lp(a) influences cardiovascular health.

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    18 to 80

Participation Criteria

Inclusion Criteria:

1. Adults ≥18 years of age and ≤80 years of age who meet either of the following criteria:

1. Elevated Lp(a) (defined as greater than or equal to 100 nmol/L)
2. Non-elevated Lp(a) (defined as less than 100 nmol/L)
2. Willing and able to provide written informed consent and comply with study procedures.

Exclusion Criteria:

1. Unable or unwilling to provide written informed consent or provide a peripheral blood sample.
2. Any life-threatening disease expected to result in death within two years of consent.
3. Any malignancy not considered cured (except basal cell carcinoma of the skin). An individual is considered cured if there has been no evidence of cancer recurrence for the five years prior to screening.
4. Uncontrolled hypertension.
5. New York Heart Association Class IV heart failure.
6. Active liver disease or liver dysfunction.
7. Active kidney disease or kidney dysfunction.
8. History of hemorrhagic stroke or other major bleeding disorder.
9. White blood cell count ≥15 x 10\^9/L.
10. Women who are pregnant or nursing.
11. Previously received ribonucleic acid therapy specifically targeting Lp(a).
12. Active infectious disease requiring systemic antibiotic or anti-viral agents.
13. Known acquired immunodeficiency syndrome, such as human immunodeficiency virus.
14. On oral steroid therapy (e.g., prednisone or other corticosteroids) or other immunosuppressive agents (e.g., methotrexate).
15. Treated autoimmune disorders.
16. Participating in another study/trial that is likely to affect the primary outcome.

Study Location

North York Diagnostic and Cardiac Centre
North York Diagnostic and Cardiac Centre
North York, Ontario
Canada

Contact Study Team

Primary Contact

Subodh Verma, MD

[email protected]
Diagnostic Assessment Centre
Diagnostic Assessment Centre
Scarborough, Ontario
Canada

Contact Study Team

Primary Contact

Subodh Verma, MD

[email protected]
Study Sponsored By
Canadian Medical and Surgical Knowledge Translation Research Group
Participants Required
More Information
Study ID: NCT06626659